The Amplified Plasmonic Exosome (Apex) system was developed by researchers at the National University of Singapore (NUS) and analyzes specific proteins in blood samples, catching the disease earlier than ever before.
The current preferred methods to diagnose dementia (of which Alzheimer’s makes up some 50-70 percent of cases) are a neuropsychological test, spinal fluid sampling and brain Positron Emission Tomography (PET) imaging, all of which are more expensive, invasive or time-consuming than the Apex system.
The current design of the Apex system can test 60 samples simultaneously, with results “available in less than one hour.” It is expected to come online in general medicine within the next five years and currently costs SGD$60 (USD$44) to administer.
At present there are roughly 50 million dementia patients worldwide but that is estimated to balloon up to 152 million by 2050, marking one of the most significant impending health crises humans face as a species. This new technology could drastically improve early detection and treatment which is critical to disease management and mitigation of symptoms.
It could also be “easily scaled up” for large-scale clinical tests and helping find the right treatment, according to research leader Shao Huilin of the NUS Institute for Health Innovation & Technology.
More about: health